Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 13/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 5/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL88462 | 0.80 | CTSK (0.41) | CTSKMEN1GAAKMT2ACTSS | |
| SCHEMBL3624040 | 0.79 | CTSK (0.34) | CTSKMEN1GAAKMT2ACTSS | |
| SCHEMBL8981186 | 0.77 | CTSK (0.43) | CTSKMEN1GAAKMT2ACTSS | |
| SCHEMBL2463123 | 0.77 | CTSK (0.35) | CTSKMEN1GAAKMT2ACTSS | |
| SCHEMBL5147739 | 0.76 | CTSK (0.39) | CTSKMEN1GAAKMT2ACTSS | |
| SCHEMBL646732 | 0.75 | CTSK (0.35) | CTSKMEN1GAAKMT2ACTSS | |
| SCHEMBL7864105 | 0.75 | CTSS (0.38) | CTSKMEN1GAAKMT2ACTSS | |
| SCHEMBL5147615 | 0.74 | AKT1 (0.38) | CTSKMEN1GAAKMT2ACTSS | |
| SCHEMBL5408412 | 0.74 | CTSK (0.41) | CTSKMEN1GAAKMT2ACTSS | |
| SCHEMBL8981149 | 0.72 | CTSK (0.43) | CTSKMEN1GAAKMT2ACTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093811-A1 | HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093811-A1 | HIV PROTEASE INHIBITORS | PRSS1, FURIN, SERPINB1 | CTSK 41/4885MEN1 2771/4885GAA 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.